Compare Neurocrine Biosciences Inc (NBIX) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Plby Group Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Plby Group Inc trades at $1.21 (market cap $139.87M). The key difference: Neurocrine Biosciences Inc is far larger — about 124.4× Plby Group Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | PLBY | |
|---|---|---|
Market Cap | $17.40B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $180.55 | $2.71 |
52-Week Low | $123.10 | $1.11 |
Enterprise Value | $16.49B | $287.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
